Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial by Vu Dinh Thiem, Nguyen Dang Quang, Nguyen Hai Tuan, Kyeongmi Cheon, Nancy Gallagher, Alain Luxembourg, Thomas Group, Cyrus Badshah

Connect to this object online.

Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants by Suzanne M. Garland, Manjula Anagani, Neerja Bhatla, Sukanta Chatterjee, Sanjay Lalwani, Cecil Ross, Thomas Group, Jianxin Lin, Alain Luxembourg, Anuj Walia, Yingmei Tu

Connect to this object online.

Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up by Susanne K. Kjaer, Mari Nygård, Karin Sundström, Christian Munk, Sophie Berger, Mensur Dzabic, Katrin Elisabeth Fridrich, Marianne Waldstrøm, Sveinung Wergeland Sørbye, Oliver Bautista, Thomas Group, Alain Luxembourg

Connect to this object online.

Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27-45 years by Ivette Maldonado, Manuel Plata, Mauricio Gonzalez, Alfonso Correa, Claudia Nossa, Anna R. Giuliano, Elmar A. Joura, Alex Ferenczy, Brigitte M. Ronnett, Mark H. Stoler, Hao Jin Zhou, Amita Joshi, Rituparna Das, Oliver Bautista, Thomas Group, Alain Luxembourg, Alfred Saah, Ulrike Kirsten Buchwald

Connect to this object online.